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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the benefits and harms of the expression and storage of breast milk during pregnancy by women with diabetes.
B A C K G R O U N D
Description of the condition
Numerous health benefits to both the mother and baby can be
ascribed to breastfeeding, in addition to the substantial cost sav-
ings it affords to families and health services (Renfrew 2012). The
World Health Organization (WHO) recommends that infants be
exclusively breastfed, whether directly from the breast or as ex-
pressed breast milk, for the first six months, that is, without any
supplements, artificial formula or solid food (WHO 2011).
Infants born to mothers who have diabetes in pregnancy (ges-
tational or pre-existing) are at increased risk of neonatal hypo-
glycaemia (low blood sugar) compared to other infants (Hanson
1993). This can be explained by their exposure to higher glucose
levels in utero than usual, with subsequent increased insulin secre-
tion. These infants may then need to adjust their insulin secretion
to deal with postnatal glucose intake levels. It is for this reason
that, in the first few days of life, many of these infants become
hypoglycaemic and will require additional glucose, provided by
donor human milk, artificial formula or via an intravenous infu-
sion, as well as the intake from breastfeeding or breast milk ex-
pressed after birth. Because euglycaemia (normal levels of glucose
in the blood) appears to be an important influence on the onset
of lactogenesis II (the copious flow of milk 30 to 40 hours after
giving birth), women with diabetes in pregnancy with hypogly-
caemia or hyperglycaemia may be at increased risk of delaying this
progression (Arthur 1994; Neubauer 1993). Thus, the infant who
is already at increased risk of morbidity related to his/her mother’s
diabetes, may also be exposed to artificial formula and separation
from the mother if transferred to a nursery facility for intravenous
fluid administration and glucose monitoring.
Further, avoidance of dietary exposure to some proteins found
in cow’s milk and the potential for a stronger immune system in
exclusively breastfed infants may decrease the likelihood of these
children subsequently developing B-cell autoimmunity and Type
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1 diabetes (Ip 2007; Newburg 2005; Silverman 1995).
Description of the intervention
Antenatal breast milk expression has historically been proposed
as a means of breast preparation (Chapman 2012a), although its
popularity declined when the evidence emerged demonstrating no
benefits in doing this (for example, Brown 1975). However, the
practice has since been utilised as a means of building up a store
of colostrum antenatally. The advantage of doing this is that, fol-
lowing birth, should additional nutrition be required, maternal
colostrum can be given instead of artificial formula (Cox 2006).
A survey of lactation consultants in Australia reported a growing
awareness of antenatal breast milk expression, even when the prac-
tice was not promoted by the individual lactation consultants who
responded to the survey (Chapman 2012b).
How the intervention might work
The storage of expressed colostrum to be given (if required) in
addition to breast milk obtained directly from the breast or ex-
pressed after birth, may avert the need for artificial formula or
intravenous fluid administration if correction of hypoglycaemia is
required. Some clinical guidelines (e.g.NICE 2008) recommend
close monitoring of the baby’s blood sugar level in the postnatal
period, with the mother and baby remaining together for care.
Should the infant become hypoglycaemic (often defined as a true
blood glucose (TBG) of < 2.6 mmol/L), a prescribed series of es-
calating interventions is followed, which may include separation
of the baby from the mother through admission to a special or
intensive care nursery if an additional feed of breast milk or for-
mula does not result in euglycaemia within an hour, or by the
time of the next feed (NETS 2009). Some hospitals mandate the
infant’s automatic admission to the special or intensive care nurs-
ery following birth, rather than mother and baby being cared for
together, for example, for the infant of a woman with Type 1 di-
abetes, or an infant of a woman with gestational diabetes who re-
quired in excess of a specified number of units of insulin daily (e.g.
Southern Health 2011). Moreover, there are substantial economic
and social costs attributable to such admissions and to separation
of the mother and her baby (Argus 2009; Figueiredo 2009). The
limited expenses involved in educating women to express and the
provision of sterile containers and freezer storage would be likely
to be considerably less than the costs of specialised nursery admis-
sion and treatment.
Potential concerns arising from breast/nipple
stimulation
Uterine contractions may result from the release of the hormone,
oxytocin, that accompanies nipple stimulation (Christensson
1989). Therefore, the potential for this intervention to cause harm
by bringing on labour early raises concern. Specifically, breast stim-
ulation may be utilised as a means of inducing labour, as reported
in a systematic review of six trials (719 women) comparing breast
stimulation with no intervention in women from 37 weeks of ges-
tation (Kavanagh 2005). The review reported a significant reduc-
tion in the proportion of women not in labour within 72 hours
(62.7% versus 93.6%, risk ratio (RR) 0.67, 95% confidence in-
terval (CI) 0.60 to 0.74). Although these findings were only sig-
nificant in women who entered the study with a favourable cervix
(that is, ready for labour), other randomised trials have demon-
strated an improvement in theBishop’s score, which gauges cervical
preparedness for labour (Damania 1992; Di Lieto 1989; Salmon
1986). To address this concern, Soltani 2012 reported a retro-
spective cohort study of 94 diabetic women. Infants of mothers
who had expressed antenatally were more likely to be born a week
earlier than infants whose mothers had not undertaken antenatal
breast milk expression.
Further concerns include the potential for earlier birth to con-
tribute to neonatal nursery admission and/or for hypoglycaemia
to develop or persist despite being given the colostrum. The study
by Soltani 2012 reported that more babies were admitted to the
special care nursery in the group that expressed milk antenatally.
Forster 2011 enrolled 43 women with diabetes in a prospective
non-randomised study of antenatal breast milk expression twice a
day for 10 minutes from 36 weeks’ gestation. Outcomes for this
group were compared with those from a retrospective audit of 89
women with diabetes who had not expressed during pregnancy.
The study reported that five women experienced uterine tighten-
ing or Braxton Hicks contractions after expressing and did not
continue this activity. Forty per cent of infants of women who had
expressed milk received artificial formula within 24 hours of birth
compared with 56% of the comparison group (RR 0.72, 95% CI
0.48 to 1.09). The finding of potentially increased rates of ad-
mission to the special care nursery in the expressing group were
of concern even though they did not reach statistical significance
(RR 1.79, 95% CI 0.94 to 3.33). The wide confidence interval
suggests that more participants would be required to confirm or
refute this concern.
Why it is important to do this review
Despite the concerns for the potential of earlier birth or neona-
tal nursery admissions for interventions to correct hypoglycaemia,
antenatal breast milk expression and storage is emerging within
clinical practice on the basis of its theoretical benefits to infants
of women with diabetes in pregnancy (for example, Cox 2010;
Ramsay Health Care 2011). The observational evidence that sug-
gests the potential for an increased risk to the mother of prema-
ture labour and to the baby of premature birth and nursery admis-
sion following such practice (Forster 2011; Soltani 2012), needs
to be followed through with a systematic review of randomised
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controlled trial evidence to determine the benefits and harms of
antenatal breast milk expression, to then inform clinical practice.
When it is determined that this practice is, or is not, beneficial to
infants, there will be implications for promoting successful breast-
feeding in the mother to reduce her risk of diabetes later in life
and for the child’s potential for developing diabetes.
O B J E C T I V E S
To evaluate the benefits and harms of the expression and storage
of breast milk during pregnancy by women with diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials, quasi-randomised trials and cluster-
randomised trials. Cross-over trials are unlikely to be appropriate
for this research question and will therefore be excluded. We will
exclude studies that are only reported in abstract form.
Types of participants
Pregnant women with diabetes (pre-existing or gestational) with
a singleton pregnancy.
Types of interventions
Randomised controlled trials that compare antenatal breast milk
expressing compared with not expressing.
Types of outcome measures
Primary outcomes
Infant
1. Exclusive breastfeeding during the period of hospital-based
care following birth.
2. Number of episodes of low blood glucose.
3. Duration of low blood glucose episode(s).
4. Administration of intravenous dextrose.
Secondary outcomes
Maternal
1. Uterine contractions during or after antenatal breast milk
expression.
2. Onset of established labour prior to 37 weeks gestation.
3. Commenced breastfeeding or milk expression following
birth.
4. Women’s satisfaction with breastfeeding.
Infant
1. Gestational age at birth.
2. Admission to special care nursery or neonatal intensive care
nursery.
3. Exclusive breastfeeding within 24 hours of discharge from
hospital-based care.
4. Any breastfeeding within 24 hours of discharge from
hospital-based care.
5. Exclusive breastfeeding at three and six months.
6. Any breastfeeding at three and six months.
7. Economic costs (as defined by trial author).
Other outcomes / considerations
We will also consider women’s views on antenatal breast milk ex-
pression in the expressing group.
Search methods for identification of studies
Electronic searches
We will contact the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register.
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of EMBASE;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
EMBASE, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
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within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
We will not apply any language restrictions.
Data collection and analysis
Selection of studies
At least two review authors will independently assess for inclu-
sion all the potential studies we identify as a result of the search
strategy. We will resolve any disagreement through discussion or,
if required, we will consult a third person.
Data extraction and management
We will design a form to extract data. For eligible studies, at least
two review authors will extract the data using the agreed form.
We will resolve discrepancies through discussion or, if required,
we will consult a third person. We will enter data into Review
Manager software (RevMan 2011) and check for accuracy.
When information regarding any of the above is unclear, we will
attempt to contact authors of the original reports to provide further
details.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve
any disagreement by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses which we undertake.
We will assess methods as:
4Antenatal breast milk expression by women with diabetes for improving infant outcomes (Protocol)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Handbook
(Higgins 2011). With reference to (1) to (6) above, we will assess
the likely magnitude and direction of the bias and whether we
consider it is likely to impact on the findings. We will explore the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk
ratio with 95% confidence intervals.
Continuous data
For continuous data, we will use the mean difference if outcomes
are measured in the same way between trials. We will use the
standardised mean difference to combine trials that measure the
same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually-randomised trials. We will adjust their sample sizes
using the methods described in the Handbook using an estimate
of the intracluster correlation co-efficient (ICC) derived from the
trial (if possible), from a similar trial or from a study of a similar
population. If we use ICCs from other sources, we will report this
and conduct sensitivity analyses to investigate the effect of varia-
tion in the ICC. If we identify both cluster-randomised trials and
individually-randomised trials, we plan to synthesise the relevant
information. We will consider it reasonable to combine the re-
sults from both if there is little heterogeneity between the study
designs and the interaction between the effect of intervention and
the choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Cross-over trials
As it unlikely that cross-over designs will be appropriate for this
research question, we will exclude them.
Other unit of analysis issues
We will exclude multiple pregnancies in order to avoid the related
issues with the unit of analysis.
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
For all outcomes, we will carry out analyses, as far as possible,
on an intention-to-treat basis, i.e. we will attempt to include all
participants randomised to each group in the analyses, and all
participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial
will be the number randomised minus any participants whose
outcomes are known to be missing.
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Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We will regard heterogeneity as
substantial if the I² is greater than 30% and either T² is greater
than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis we will investi-
gate reporting biases (such as publication bias) using funnel plots.
We will assess
funnel plot asymmetry visually. If asymmetry is suggested by a
visual assessment, we will perform exploratory analyses to investi-
gate it.
Data synthesis
We will carry out statistical analysis using the Review Manager
software (RevMan 2011). We will use fixed-effect meta-analysis
for combining datawhere it is reasonable to assume that studies are
estimating the same underlying treatment effect: i.e. where trials
are examining the same intervention, and the trials’ populations
and methods are judged sufficiently similar. If there is clinical het-
erogeneity sufficient to expect that the underlying treatment ef-
fects differ between trials, or if substantial statistical heterogeneity
is detected, we will use random-effects meta-analysis to produce
an overall summary if an average treatment effect across trials is
considered clinically meaningful. The random-effects summary
will be treated as the average range of possible treatment effects
and we will discuss the clinical implications of treatment effects
differing between trials. If the average treatment effect is not clin-
ically meaningful, we will not combine trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it us-
ing subgroup analyses and sensitivity analyses. We will consider
whether an overall summary is meaningful, and if it is, use ran-
dom-effects analysis to produce it.
We plan to carry out the following subgroup analysis.
• Type of diabetes: gestational versus Type 1 versus Type 2.
The following outcome will be used in subgroup analysis.
• Exclusive breastfeeding during the period of hospital-based
care following birth.
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2011). We will report the results of
subgroup analyses quoting the χ2 statistic and P value, and the
interaction test I² value.
Sensitivity analysis
We will carry out sensitivity analysis to explore the effects of trial
quality assessed by allocation concealment and other risk of bias
components, by omitting studies rated as ’high risk of bias’ for
these components. This will be restricted to the primary outcomes.
A C K N OW L E D G E M E N T S
Aspart of the pre-publication editorial process, this reviewhas been
commented on by two peers (an editor and referee who is external
to the editorial team), a member of the Pregnancy and Childbirth
Group’s international panel of consumers and the Group’s Statis-
tical Adviser.
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